In such cases, early switching to immune checkpoint inhibitor treatments may be worth giving careful consideration for patients carrying EGFR‐mutated NSCLC with intermediate or high PD‐L1 expression, due to the potential for early resistance to osimertinib. Here, EGFR is linked to non-small cell lung carcinoma.